These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 6427998

  • 21. BCG immunopotentiation of an antitumor response: evidence for a cell-mediated mechanism.
    Hawrylko E.
    J Natl Cancer Inst; 1975 Aug; 55(2):413-23. PubMed ID: 808641
    [Abstract] [Full Text] [Related]

  • 22. Eradication of syngeneic tumor (Meth A fibrosarcoma) from mice by adoptive immunotherapy of immunized spleen cells induced by Corynebacterium parvum-pyridine extract residue.
    Mukai K, Horimi T, Orita K.
    Acta Med Okayama; 1988 Dec; 42(6):301-10. PubMed ID: 3266420
    [Abstract] [Full Text] [Related]

  • 23. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
    Shu S, Rosenberg SA.
    J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
    [Abstract] [Full Text] [Related]

  • 24. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.
    Uyttenhove C, Maryanski J, Boon T.
    J Exp Med; 1983 Mar 01; 157(3):1040-52. PubMed ID: 6187879
    [Abstract] [Full Text] [Related]

  • 25. Functional heterogeneity of lymphocytic choriomeningitis virus-specfic T lymphocytes. I. Identification of effector amd memory subsets.
    Johnson ED, Cole GA.
    J Exp Med; 1975 Apr 01; 141(4):866-81. PubMed ID: 47887
    [Abstract] [Full Text] [Related]

  • 26. Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice.
    Germain RN, Williams RM, Benacerraf B.
    Am J Pathol; 1976 Dec 01; 85(3):661-74. PubMed ID: 826167
    [Abstract] [Full Text] [Related]

  • 27. Suppressor T cells and the regression phase of syngeneic intradermally developing p-815 mastocytomas.
    Bertschmann M, Schären B, Lüscher EF.
    Eur J Cancer Clin Oncol; 1982 Apr 01; 18(4):405-11. PubMed ID: 6214404
    [Abstract] [Full Text] [Related]

  • 28. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization.
    Bour H, Horvath C, Lurquin C, Cerottini JC, MacDonald HR.
    J Immunol; 1998 Jun 01; 160(11):5522-9. PubMed ID: 9605156
    [Abstract] [Full Text] [Related]

  • 29. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815.
    Brichard VG, Warnier G, Van Pel A, Morlighem G, Lucas S, Boon T.
    Eur J Immunol; 1995 Mar 01; 25(3):664-71. PubMed ID: 7705394
    [Abstract] [Full Text] [Related]

  • 30. The antimetastatic function of concomitant antitumor immunity. I. Host Ly-1+2+ effector T cells prevent the enumeration of metastatic tumor cells in a biological assay.
    Dye SE.
    J Immunol; 1986 Feb 15; 136(4):1504-9. PubMed ID: 3080525
    [Abstract] [Full Text] [Related]

  • 31. The effect of iron-deficiency anemia on cytolytic activity of mice spleen and peritoneal cells against allogenic tumor cells.
    Kuvibidila SR, Baliga BS, Suskind RM.
    Am J Clin Nutr; 1983 Aug 15; 38(2):238-44. PubMed ID: 6410896
    [Abstract] [Full Text] [Related]

  • 32. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S, Yamamoto H, Fujii Y, Arai S.
    Cancer Res; 1986 Nov 15; 46(11):5548-52. PubMed ID: 2428480
    [Abstract] [Full Text] [Related]

  • 33. The in vivo immunosuppressive action of suppressor cells from alloantigen-cyclosporine-treated mice and the capacity of spleen cells to release interleukins and gamma-interferon.
    Yoshimura N, Matsui S, Hamashima T, Kita M, Oka T.
    Transplantation; 1988 Jan 15; 45(1):157-62. PubMed ID: 2962348
    [Abstract] [Full Text] [Related]

  • 34. Corynebacterium parvum as a therapeutic antitumor agent in mice. I. Systemic effects from intravenous injection.
    Scott MT.
    J Natl Cancer Inst; 1974 Sep 15; 53(3):855-60. PubMed ID: 4213015
    [No Abstract] [Full Text] [Related]

  • 35. Novel phenotype associated with in vivo activated CTL precursors.
    Oughton JA, Kerkvliet NI.
    Clin Immunol; 1999 Mar 15; 90(3):323-33. PubMed ID: 10075861
    [Abstract] [Full Text] [Related]

  • 36. Immunomodulation by corynebacterium parvum in two strains of guinea-pigs and the effect of cyclophosphamide.
    Gauthier-Rahman S.
    Immunology; 1981 Jan 15; 42(1):99-109. PubMed ID: 7461727
    [Abstract] [Full Text] [Related]

  • 37. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.
    Cerundolo V, Lahaye T, Horvath C, Zanovello P, Collavo D, Engers HD.
    Eur J Immunol; 1987 Feb 15; 17(2):173-8. PubMed ID: 3030766
    [Abstract] [Full Text] [Related]

  • 38. Presence of CD4+ T suppressor cells in mice rendered unresponsive to tumor antigens by intravenous injection of irradiated tumor cells.
    Rakhmilevich AL, North RJ, Dye ES.
    Int J Cancer; 1993 Sep 09; 55(2):338-43. PubMed ID: 8103762
    [Abstract] [Full Text] [Related]

  • 39. Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma.
    Prell RA, Kerkvliet NI.
    J Immunol; 1997 Mar 15; 158(6):2695-703. PubMed ID: 9058803
    [Abstract] [Full Text] [Related]

  • 40. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA, Shu S, Chou T, Perry-Lalley D, Chang AE.
    J Immunol; 1988 Aug 01; 141(3):1047-53. PubMed ID: 3260908
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.